logo
More early stage colon cancers found due to more screenings, research shows

More early stage colon cancers found due to more screenings, research shows

Yahoo18 hours ago
As more people aged 45-49 are getting screened for colon cancer, more early stage diagnoses are being made, according to new research from the American Cancer Society.
The research, published in two studies Monday in the Journal of the American Medical Association, showed increases in screenings among those younger than 50 is linked to rises in earlier diagnosis. One study showed an annual increase of 1.1% from 2004 to 2019 jumped to 12% from 2019 to 2022 for colorectal cancer incidence among people aged 45 to 49, while another study showed screenings among U.S. adults aged 45 to 49 increase 62% from 2019 to 2023.
The recommended age to begin colorectal screening was lowered from 50 to 45 by the ACS in 2018 and by the U.S. Preventive Services Task Force in 2021.
In a news release Monday, Elizabeth Schafer, lead author and surveillance and health equity scientist, called the findings "promising news."
"The uptick of cases is likely due to first-time screening in the wake of new recommendations for younger average-risk adults to begin testing for colorectal cancer earlier," Schafer explained.
Another lead author, Jessica Star, who does cancer risk factors and screening surveillance research at the ACS, said it's "thrilling" to see increases in screening rates among younger adults as well as its likely ties into rises in earlier stage diagnosis.
Still, she warned there's a long way to go.
"Screening for colorectal caner in ages 45-49 remains suboptimal and has not increased equitably by both education attainment and insurance status," Star said in the release.
Recently, medical associations expressed concern after a report that Health and Human Services Secretary Robert F. Kennedy may remove all members of the U.S. Preventive Services Task Force, a panel of independent medical experts whose recommendations help guide insurance companies and doctors' decisions about a range of preventive health measures, like cancer screenings.
Dr. Thomas Lew, an assistant clinical professor of medicine at the Stanford University School of Medicine and attending physician of hospital medicine at Stanford Health Care Tri-Valley, recently told CBS News that a change like this would "greatly damage all the work we've done in preventative care, making people sicker, and driving up costs and premiums."
"To put it mildly, this is extremely concerning — and doing the opposite of making America healthy," Lew said.
In a statement to CBS News at the time, an HHS spokesperson said, "No final decision has been made on how the USPSTF can better support HHS' mandate to Make America Healthy Again."
How safe is our Social Security safety net?
Russia downplays Trump's announcement about nuclear submarines
Former Trump prosecutor under investigation for potential Hatch Act violations
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

3 Healthcare Stocks Paying the Highest Dividends of 2025
3 Healthcare Stocks Paying the Highest Dividends of 2025

Yahoo

time14 minutes ago

  • Yahoo

3 Healthcare Stocks Paying the Highest Dividends of 2025

Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 3 Healthcare Stocks Paying the Highest Dividends of 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How to Stay Safe as Smoky Air Blankets US
How to Stay Safe as Smoky Air Blankets US

Bloomberg

time16 minutes ago

  • Bloomberg

How to Stay Safe as Smoky Air Blankets US

Hi! It's Madison in New York. If you've found it harder to breathe recently, you're not alone. But first... A couple months ago, I noticed that I was coughing a lot on my weekly runs. I've been running for years and I'm currently training for my third marathon, so it wasn't the result of simply being out-of-shape. Before long, I realized my cough was much worse on days when the air quality in New York was particularly bad. Recently, that's felt like more and more often.

FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial
FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial

Yahoo

time42 minutes ago

  • Yahoo

FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial

The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group's investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the trial will focus on supporting prolonged heart perfusion leveraging the OCS Heart System. OCS Heart comprises a portable, warm perfusion system, which is said to maintain a donor heart in a metabolically active state, allowing physicians to monitor and assess the heart's condition and viability. Part B aims to demonstrate the OCS Heart perfusion's superiority in donation after brain death (DBD) cases over traditional static cold storage methods. This part is aimed at supporting the potential expansion of the system use for DBD hearts, which are currently ineligible for OCS perfusion and preservation. The anticipated sample size for both parts of the trial is set to exceed 650 subjects, which the company believes would make the largest heart preservation for transplant trial ever worldwide. TransMedics Group CEO and president Waleed Hassanein said: "The recent FDA approvals to initiate our Next-Gen OCS ENHANCE Heart and DENOVO Lung trials mark key milestones in our ongoing commitment to transforming the standard of care and addressing the major clinical needs of the cardiothoracic transplant community. "We are thrilled to be in a position to initiate both trials in the fourth quarter of 2025 while we continue to work collaboratively with the FDA to address any remaining questions related to pre-clinical testing. 'As I have stated before, we hope these two trials will be major catalysts for clinical adoption for both heart and lung throughout 2026 and beyond." In 2023, the company completed the acquisition of a premier US charter flight operator, Summit Aviation. This move has established TransMedics Aviation as the first dedicated national air logistics provider exclusively for organ transplantation in the US. "FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Connectez-vous pour accéder à votre portefeuille

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store